D&D Pharmatech Selected to Present at 2026 JPMorgan Healthcare Conference

D&D Pharmatech announced on the 5th that it has been chosen to present in the APAC track at the 2026 JPMorgan Healthcare Conference in San Francisco, one of the industry’s most influential global gatherings. The company plans to share interim 12- and 24-week Phase 2 data for its MASH candidate DD01, a dual GLP-1/glucagon receptor agonist currently in U.S. clinical trials.

Interim Clinical Progress Positions DD01 for Global Attention

DD01 is being evaluated in a 48-week Phase 2 trial for MASLD/MASH patients, with earlier 12-week data showing rapid liver fat reduction and competitive weight-loss performance. Full patient dosing is expected to conclude this year, and top-line outcomes, including biopsy-based fibrosis improvements, are scheduled for release in May 2026.

Potential Partnership Momentum at JPMorgan

With its selection as a presenting company, D&D Pharmatech plans to advance technology-transfer discussions for DD01 with several multinational pharmaceutical companies. Multiple meetings with Big Pharma have already been arranged, with further sessions being coordinated ahead of the conference.